{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T01:35:05Z","timestamp":1771464905379,"version":"3.50.1"},"reference-count":33,"publisher":"Walter de Gruyter GmbH","issue":"1","license":[{"start":{"date-parts":[[2021,8,2]],"date-time":"2021-08-02T00:00:00Z","timestamp":1627862400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,8,2]],"date-time":"2021-08-02T00:00:00Z","timestamp":1627862400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"NCN","award":["DEC-2011\/01\/B\/NZ5\/05346"],"award-info":[{"award-number":["DEC-2011\/01\/B\/NZ5\/05346"]}]},{"name":"Medical University of Warsaw"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch. Immunol. Ther. Exp."],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>B-cell activating factor (BAFF), a member of tumor necrosis factor family, activates B cells, promotes their survival and proliferation. BAFF is considered to have an influence on development of autoimmune diseases including myasthenia gravis (MG). We aimed to evaluate BAFF serum levels in MG patients, their potential connection with therapy and course of MG. Cross-sectional study. Two hundred eighteen adult patients with MG (67% women, age: 18\u201389\u00a0years, 82.6% AChR antibody seropositive (AChRAb(+)). Serum BAFF levels, their relationship with severity of clinical symptoms, therapy conducted, clinical and demographic features and other factors were analyzed. Patients with AChRAb(+) MG demonstrated significantly higher BAFF levels than MuSK-MG patients (831.2\u2009\u00b1\u2009285.4\u00a0pg\/ml vs. 745.6\u2009\u00b1\u2009633.4\u00a0pg\/ml, respectively; <jats:italic>p<\/jats:italic>\u2009=\u20090.030). Serum BAFF levels in women were significantly higher than in men (855.9\u2009\u00b1\u2009302.5 vs. 756.6\u2009\u00b1\u2009289.4, respectively; <jats:italic>p<\/jats:italic>\u2009=\u20090.017). Mean serum BAFF level was significantly decreased in patients who were ever treated with corticosteroids (CS) (770.4\u2009\u00b1\u2009327.8\u00a0pg\/ml vs. 891.3\u2009\u00b1\u2009246.1\u00a0pg\/ml, respectively; <jats:italic>p<\/jats:italic>\u2009=\u20090.001). Thymoma-MG patients demonstrated significantly lower BAFF levels (671.2\u2009\u00b1\u2009244.9 vs. 833.5\u2009\u00b1\u2009302.4, respectively; <jats:italic>p<\/jats:italic>\u2009=\u20090.044). Thymectomized patients did not differ in BAFF levels from the MG patients who had not undergone thymectomy. In multiple linear regression model, recent CS therapy and male sex were found to be independent predictors of lower BAFF levels. Serum BAFF level is decreased in patients treated with CS, which may suggest inhibiting influence of CS on BAFF\u2014a potential mechanism contributing to the effectiveness of such therapy.<\/jats:p>","DOI":"10.1007\/s00005-021-00626-5","type":"journal-article","created":{"date-parts":[[2021,8,2]],"date-time":"2021-08-02T15:03:30Z","timestamp":1627916610000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Lower BAFF Levels in Myasthenic Patients Treated with Glucocorticoids"],"prefix":"10.2478","volume":"69","author":[{"given":"Ewa","family":"Sobieszczuk","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4585-3851","authenticated-orcid":false,"given":"Piotr","family":"Szczudlik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Justyna","family":"Kubiszewska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beata","family":"Szyluk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marta","family":"Lipowska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ma\u0142gorzata","family":"Dutkiewicz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Kostera-Pruszczyk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"374","published-online":{"date-parts":[[2021,8,2]]},"reference":[{"key":"626_CR1","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/j.cytogfr.2013.12.011","volume":"25","author":"M Chen","year":"2014","unstructured":"Chen M, Lin X, Liu Y et al (2014) The function of BAFF on T helper cells in autoimmunity. Cytokine Growth Factor Rev 25:301\u2013305. https:\/\/doi.org\/10.1016\/j.cytogfr.2013.12.011","journal-title":"Cytokine Growth Factor Rev"},{"key":"626_CR2","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1038\/s41582-018-0110-z","volume":"15","author":"MC Dalakas","year":"2019","unstructured":"Dalakas MC (2019) Immunotherapy in myasthenia gravis in the era of biologics. Nat Rev Neurol 15:113\u2013124. https:\/\/doi.org\/10.1038\/s41582-018-0110-z","journal-title":"Nat Rev Neurol"},{"key":"626_CR3","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1186\/s12881-019-0906-8","volume":"20","author":"H Deng","year":"2019","unstructured":"Deng H, Wang J, Kong X et al (2019) Associations of BAFF rs2893321 polymorphisms with myasthenia gravis susceptibility. BMC Med Genet 20:168. https:\/\/doi.org\/10.1186\/s12881-019-0906-8","journal-title":"BMC Med Genet"},{"key":"626_CR4","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1111\/cei.13039","volume":"190","author":"G Ferraccioli","year":"2017","unstructured":"Ferraccioli G, Gremese E (2017) B cell activating factor (BAFF) and BAFF receptors: fakes and facts. Clin Exp Immunol 190:291\u2013292. https:\/\/doi.org\/10.1111\/cei.13039","journal-title":"Clin Exp Immunol"},{"key":"626_CR5","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000077","volume":"2","author":"JT Guptill","year":"2015","unstructured":"Guptill JT, Yi JS, Sanders DB et al (2015) Characterization of B cells in muscle-specific kinase antibody myasthenia gravis. Neurol Neuroimmunol Neuroinflamm 2:e77. https:\/\/doi.org\/10.1212\/NXI.0000000000000077","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"626_CR6","doi-asserted-by":"publisher","first-page":"e1425","DOI":"10.1212\/WNL.0000000000005323","volume":"90","author":"K Hewett","year":"2018","unstructured":"Hewett K, Sanders DB, Grove RA et al (2018) Randomized study of adjunctive belimumab in participants with generalized myasthenia gravis. Neurology 90:e1425\u2013e1434. https:\/\/doi.org\/10.1212\/WNL.0000000000005323","journal-title":"Neurology"},{"key":"626_CR7","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1038\/85520","volume":"7","author":"W Hoch","year":"2001","unstructured":"Hoch W, McConville J, Helms S et al (2001) Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies. Nat Med 7:365\u2013368. https:\/\/doi.org\/10.1038\/85520","journal-title":"Nat Med"},{"key":"626_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2019.108796","volume":"114","author":"S Hu","year":"2019","unstructured":"Hu S, Wang R, Zhang M et al (2019) BAFF promotes T cell activation through the BAFF-BAFF-R-PI3K-Akt signaling pathway. Biomed Pharmacother 114:108796. https:\/\/doi.org\/10.1016\/j.biopha.2019.108796","journal-title":"Biomed Pharmacother"},{"key":"626_CR9","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.122525","volume":"3","author":"W Huang","year":"2018","unstructured":"Huang W, Quach TD, Dascalu C et al (2018) Belimumab promotes negative selection of activated autoreactive B cells in systemic lupus erythematosus patients. JCI Insight 3:e122525. https:\/\/doi.org\/10.1172\/jci.insight.122525","journal-title":"JCI Insight"},{"key":"626_CR10","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.clim.2017.01.005","volume":"176","author":"N Ibtehaj","year":"2017","unstructured":"Ibtehaj N, Huda R (2017) High-dose BAFF receptor specific mAb-siRNA conjugate generates Fas-expressing B cells in lymph nodes and high-affinity serum autoantibody in a myasthenia mouse model. Clin Immunol 176:122\u2013130. https:\/\/doi.org\/10.1016\/j.clim.2017.01.005","journal-title":"Clin Immunol"},{"key":"626_CR11","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1111\/j.0105-2896.2005.00219.x","volume":"204","author":"SL Kalled","year":"2005","unstructured":"Kalled SL (2005) The role of BAFF in immune function and implications for autoimmunity. Immunol Rev 204:43\u201354. https:\/\/doi.org\/10.1111\/j.0105-2896.2005.00219.x","journal-title":"Immunol Rev"},{"key":"626_CR12","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1002\/mus.25162","volume":"54","author":"SY Kang","year":"2016","unstructured":"Kang SY, Kang CH, Lee KH (2016) B-cell-activating factor is elevated in serum of patients with myasthenia gravis. Muscle Nerve 54:1030\u20131033. https:\/\/doi.org\/10.1002\/mus.25162","journal-title":"Muscle Nerve"},{"key":"626_CR13","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1007\/s12026-013-8466-z","volume":"57","author":"WN Khan","year":"2013","unstructured":"Khan WN, Wright JA, Kleiman E et al (2013) B-lymphocyte tolerance and effector function in immunity and autoimmunity. Immunol Res 57:335\u2013353. https:\/\/doi.org\/10.1007\/s12026-013-8466-z","journal-title":"Immunol Res"},{"key":"626_CR14","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.jneuroim.2008.05.010","volume":"199","author":"JY Kim","year":"2008","unstructured":"Kim JY, Yang Y, Moon JS et al (2008) Serum BAFF expression in patients with myasthenia gravis. J Neuroimmunol 199:151\u2013154. https:\/\/doi.org\/10.1016\/j.jneuroim.2008.05.010","journal-title":"J Neuroimmunol"},{"key":"626_CR15","doi-asserted-by":"publisher","DOI":"10.1002\/brb3.537","volume":"6","author":"J Kubiszewska","year":"2016","unstructured":"Kubiszewska J, Szyluk B, Szczudlik P et al (2016) Prevalence and impact of autoimmune thyroid disease on myasthenia gravis course. Brain Behav 6:e00537. https:\/\/doi.org\/10.1002\/brb3.537","journal-title":"Brain Behav"},{"key":"626_CR16","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.jaut.2012.05.009","volume":"39","author":"A Lahiri","year":"2012","unstructured":"Lahiri A, Pochard P, Le Pottier L et al (2012) The complexity of the BAFF TNF-family members: implications for autoimmunity. J Autoimmun 39:189\u2013198. https:\/\/doi.org\/10.1016\/j.jaut.2012.05.009","journal-title":"J Autoimmun"},{"key":"626_CR17","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.cca.2016.09.004","volume":"462","author":"JD Lin","year":"2016","unstructured":"Lin JD, Wang YH, Fang WF et al (2016) Serum BAFF and thyroid autoantibodies in autoimmune thyroid disease. Clin Chim Acta 462:96\u2013102. https:\/\/doi.org\/10.1016\/j.cca.2016.09.004","journal-title":"Clin Chim Acta"},{"key":"626_CR18","doi-asserted-by":"publisher","DOI":"10.1212\/wnl.26.11.1054","author":"JM Lindstrom","year":"1976","unstructured":"Lindstrom JM, Seybold ME, Lennon VA et al (1976) Antibody to acetylcholine receptor in myasthenia gravis. Prevalence, clinical correlates, and diagnostic value. Neurology. https:\/\/doi.org\/10.1212\/wnl.26.11.1054","journal-title":"Neurology"},{"key":"626_CR19","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1007\/s12031-016-0787-7","volume":"60","author":"G Mameli","year":"2016","unstructured":"Mameli G, Cossu D, Caggiu E et al (2016) Soluble BAFF Level is not correlated to Mycobacterium avium subspecies paratuberculosis antibodies and increases after interferon-\u03b2 therapy in multiple sclerosis patients. J Mol Neurosci 60:91\u201393. https:\/\/doi.org\/10.1007\/s12031-016-0787-7","journal-title":"J Mol Neurosci"},{"key":"626_CR20","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.clim.2009.09.007","volume":"134","author":"K Migita","year":"2010","unstructured":"Migita K, Ilyassova B, Kovzel EF et al (2010) Serum BAFF and APRIL levels in patients with PBC. Clin Immunol 134:217\u2013225. https:\/\/doi.org\/10.1016\/j.clim.2009.09.007","journal-title":"Clin Immunol"},{"key":"626_CR21","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1126\/science.285.5425.260","volume":"285","author":"PA Moore","year":"1999","unstructured":"Moore PA, Belvedere O, Orr A et al (1999) BLyS: member of the tumor necrosis factor family and B lymphocyte stimulator. Science 285:260\u2013263. https:\/\/doi.org\/10.1126\/science.285.5425.260","journal-title":"Science"},{"key":"626_CR22","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s41232-016-0015-4","volume":"36","author":"S Nakayamada","year":"2016","unstructured":"Nakayamada S, Tanaka Y (2016) BAFF- and APRIL-targeted therapy in systemic autoimmune diseases. Inflamm Regen 36:6. https:\/\/doi.org\/10.1186\/s41232-016-0015-4","journal-title":"Inflamm Regen"},{"key":"626_CR23","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.molimm.2012.06.013","volume":"53","author":"R Panchanathan","year":"2013","unstructured":"Panchanathan R, Choubey D (2013) Murine BAFF expression is up-regulated by estrogen and interferons: implications for sex bias in the development of autoimmunity. Mol Immunol 53:15\u201323. https:\/\/doi.org\/10.1016\/j.molimm.2012.06.013","journal-title":"Mol Immunol"},{"key":"626_CR24","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1016\/j.coi.2011.10.007","volume":"23","author":"S Pillai","year":"2011","unstructured":"Pillai S, Mattoo H, Cariappa A (2011) B cells and autoimmunity. Curr Opin Immunol 23:721\u2013731. https:\/\/doi.org\/10.1016\/j.coi.2011.10.007","journal-title":"Curr Opin Immunol"},{"key":"626_CR25","doi-asserted-by":"publisher","first-page":"2167","DOI":"10.1016\/j.intimp.2011.09.014","volume":"11","author":"Q Qin","year":"2011","unstructured":"Qin Q, Chang Y, Wang D et al (2011) TACI-Ig induces immune balance of Th cells in MLN via BLyS\/APRIL-receptors signaling in rats with adjuvant-induced arthritis. Int Immunopharmacol 11:2167\u20132175. https:\/\/doi.org\/10.1016\/j.intimp.2011.09.014","journal-title":"Int Immunopharmacol"},{"key":"626_CR26","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1001\/archneur.65.10.1358","volume":"65","author":"S Ragheb","year":"2008","unstructured":"Ragheb S, Lisak R, Lewis R et al (2008) A potential role for B-cell activating factor in the pathogenesis of autoimmune myasthenia gravis. Arch Neurol 65:1358\u20131362. https:\/\/doi.org\/10.1001\/archneur.65.10.1358","journal-title":"Arch Neurol"},{"key":"626_CR27","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0005456","volume":"4","author":"M Rauch","year":"2009","unstructured":"Rauch M, Tussiwand R, Bosco N et al (2009) Crucial role for BAFF-BAFF-R signaling in the survival and maintenance of mature B cells. PLoS ONE 4:e5456. https:\/\/doi.org\/10.1371\/journal.pone.0005456","journal-title":"PLoS ONE"},{"key":"626_CR28","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1084\/jem.189.11.1747","volume":"189","author":"P Schneider","year":"1999","unstructured":"Schneider P, MacKay F, Steiner V et al (1999) BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth. J Exp Med 189:1747\u20131756. https:\/\/doi.org\/10.1084\/jem.189.11.1747","journal-title":"J Exp Med"},{"key":"626_CR29","doi-asserted-by":"publisher","first-page":"2284","DOI":"10.1007\/s00415-011-6092-z","volume":"258","author":"F Scuderi","year":"2011","unstructured":"Scuderi F, Alboini PE, Bartoccioni E et al (2011) BAFF serum levels in myasthenia gravis: effects of therapy. J Neurol 258:2284\u20132285. https:\/\/doi.org\/10.1007\/s00415-011-6092-z","journal-title":"J Neurol"},{"key":"626_CR30","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.imlet.2010.03.007","volume":"131","author":"LK Swee","year":"2010","unstructured":"Swee LK, Tardivel A, Schneider P et al (2010) Rescue of the mature B cell compartment in BAFF-deficient mice by treatment with recombinant Fc-BAFF. Immunol Lett 131:40\u201348. https:\/\/doi.org\/10.1016\/j.imlet.2010.03.007","journal-title":"Immunol Lett"},{"key":"626_CR31","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.imlet.2018.01.010","volume":"196","author":"X Tang","year":"2018","unstructured":"Tang X, Zhang L, Wei W (2018) Roles of TRAFs in NF-\u03baB signaling pathways mediated by BAFF. Immunol Lett 196:113\u2013118. https:\/\/doi.org\/10.1016\/j.imlet.2018.01.010","journal-title":"Immunol Lett"},{"key":"626_CR32","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.jneuroim.2006.05.023","volume":"178","author":"M Thangarajh","year":"2006","unstructured":"Thangarajh M, Masterman T, Helgeland L et al (2006) The thymus is a source of B-cell-survival factors-APRIL and BAFF-in myasthenia gravis. J Neuroimmunol 178:161\u2013166. https:\/\/doi.org\/10.1016\/j.jneuroim.2006.05.023","journal-title":"J Neuroimmunol"},{"key":"626_CR33","doi-asserted-by":"publisher","first-page":"E755","DOI":"10.1210\/jc.2011-2614","volume":"97","author":"G Vannucchi","year":"2012","unstructured":"Vannucchi G, Covelli D, Curr\u00f2 N et al (2012) Serum BAFF concentrations in patients with Graves\u2019 disease and orbitopathy before and after immunosuppressive therapy. J Clin Endocrinol Metab 97:E755-759. https:\/\/doi.org\/10.1210\/jc.2011-2614","journal-title":"J Clin Endocrinol Metab"}],"container-title":["Archivum Immunologiae et Therapiae Experimentalis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00005-021-00626-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00005-021-00626-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00005-021-00626-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,2]],"date-time":"2024-01-02T20:49:35Z","timestamp":1704228575000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00005-021-00626-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,2]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["626"],"URL":"https:\/\/doi.org\/10.1007\/s00005-021-00626-5","relation":{},"ISSN":["0004-069X","1661-4917"],"issn-type":[{"value":"0004-069X","type":"print"},{"value":"1661-4917","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,2]]},"assertion":[{"value":"3 March 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 July 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 August 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"None declared.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Study was approved by local ethics committee (KB\/186\/2007).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}],"article-number":"22"}}